Telomeres and Dementia; Cell Therapy and Parkinson’s; Next Up: In Utero Neurology

Can leucocyte telomere length predict dementia? (General Psychiatry)

An artificial intelligence system remotely assessed the motor performance of people with Parkinson’s disease. (npj Digital Medicine)

Growing pains in children’s lower limbs were linked with migraine. (Headache)

The C5 complement inhibitor ravulizumab (Ultomiris) was not approved for neuromyelitis optica spectrum disorder, with the FDA requesting changes to the drug’s risk evaluation and mitigation strategy (REMS), AstraZeneca said.

Investigational cell therapy for Parkinson’s disease had taken a new turn. (MIT Technology Review)

Racial disparities existed in frontotemporal dementia severity, functional impairment, and neuropsychiatric symptoms, cross-sectional data suggested. (JAMA Neurology)

A version of the human leukocyte antigen gene DR4 may protect against Parkinson’s disease, Alzheimer’s dementia, and other neurodegenerative disorders. (PNAS)

The next neurology frontier is in utero with a new set of ethical challenges, researchers said. (JAMA Neurology)

A genome-wide association study meta-analysis of over 29,000 people with epilepsy identified 26 risk loci. (Nature Genetics)

Adults with spinal muscular atrophy had more physical and mental comorbidities than the general population, claims data showed. (Orphanet Journal of Rare Diseases)

Users of the social platform Threads were blocked from seeing posts about long COVID and COVID. (Washington Post)

Bennet Omalu, MD, MPH, whose work about chronic traumatic encephalopathy was the focus of the movie “Concussion,” provided expert testimony on head trauma in a murder trial this week. (San Francisco Standard)

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Please enable JavaScript to view the

comments powered by Disqus.